Articles related to Oncology, Radiation

The emergence of novel agents including BTK degraders, next-generation BCL2 inhibitors, and optimized combination approaches is reshaping the CLL treatment landscape, with multiple trials demonstrating high uMRD rates, improved progression-free survival, and manageable toxicity profiles across different patient populations.

Long-term follow-up data demonstrate a significant overall survival advantage with combination therapy, showing a hazard ratio of 0.54 (95% CI 0.31-0.95) for radiation plus temozolomide versus radiation alone in grade II gliomas.

Family engagement in cancer care extends beyond emotional support, creating tangible impacts on patient outcomes and treatment adherence.

A comprehensive analysis of 176,601 cancer cases demonstrates that long-acting reversible contraceptives offer a cancer risk profile comparable to oral contraceptives, with data showing a 20-30% reduction in gynecologic cancer risk and a modest increase in breast cancer risk that returns to baseline after cessation.

Comprehensive genetic profiling now plays a central role in ovarian cancer management, with mandatory offering of both germline and somatic testing for all patients at diagnosis.

Digital platforms are enabling oncologists to access global expertise through virtual tumor boards, particularly benefiting practitioners in resource-limited settings who previously lacked access to multidisciplinary consultation.